Equillium Inc (EQ)
NASDAQ:EQ
Want to see EQ full AI Analyst Report?
EQ Stock Chart & Stats
$2.05
-$0.05(-6.85%)
At close: 4:00 PM EST
$2.05
-$0.05(-6.85%)
Day’s Range― - ―
52-Week Range$0.29 - $3.45
Previous CloseN/A
Volume484.47K
Average Volume (3M)883.61K
Market Cap
$192.84M
Enterprise Value$45.58M
Total Cash (Recent Filing)$61.32M
Total Debt (Recent Filing)$692.00K
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding63,226,555
10 Day Avg. Volume862,141
30 Day Avg. Volume883,611
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.98
Price to Sales (P/S)0.00
P/FCF Ratio-6.25
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-576.95
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$7.57Price Target Upside269.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low debt reduces bankruptcy and interest‑service risk and gives management flexibility to prioritize R&D without fixed debt obligations. For a clinical‑stage biotech this durable balance‑sheet strength supports multi‑quarter development programs and partner negotiations.
Recent Financing Extends RunwayA material private placement that meaningfully extends cash runway reduces immediate liquidity pressure and allows planned clinical work to proceed. That financing lowers short‑term funding risk and increases the chance of hitting development milestones that enable partnering or licensing over the coming months.
Focused Clinical‑stage PipelineA clear scientific focus on immunomodulatory biologics and a lead monoclonal program provides a coherent strategy likely to attract partners or acquirers. Pipeline concentration on validated immune targets offers structural commercial upside if clinical results are positive and supports long‑term asset value creation.
Bears Say
Near‑zero RevenueThe abrupt loss of commercial/partnered revenue leaves the company without meaningful organic cash generation. Absent product sales or recurring licensing receipts, Equillium must rely on external financing to fund R&D, making long‑term program execution and independence contingent on successful capital raises or partnerships.
Heavy Cash BurnSustained negative operating and free cash flow indicates persistent funding needs and pressure on liquidity if financing stalls. Ongoing burn forces prioritization of programs, can delay trials, and raises the probability of disruptive financing decisions that affect long‑term execution and strategic optionality.
Capital Structure Dilution RiskBoard approvals to increase authorized shares and permit a wide reverse split range create clear capacity for future equity issuance and price management. This structural flexibility raises the likelihood of dilution over time, which can erode existing holders' ownership and complicate long‑term shareholder alignment.
Equillium News
EQ FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest stock price was $0.29 and its highest was $3.45 in the past 12 months.
What is Equillium Inc’s market cap?
Equillium Inc’s market cap is $192.84M.
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Aug 12, 2026 which is in 45 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on May 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.014.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -0.05.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 63,226,555 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 12.121%.
Which hedge fund is a major shareholder of Equillium Inc?
Currently, no hedge funds are holding shares in EQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Equillium Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.57 (269.34% Upside)
$7.57 (269.34% Upside)
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $723.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 28.1%
Last 30 Days ▲ 28.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.18%
12-Months-Change
Fundamentals
Return on Equity
-61.43%
Trailing 12-Months
Asset Growth
277.09%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
EQ Stock 12 Month Forecast
Average Price Target
$7.57
▲(269.34% Upside)
Technical Analysis
Ownership Overview
13.05% Insiders
3.30% Mutual Funds
38.11% Other Institutional Investors
42.67% Public Companies and
Individual Investors